Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Holdings Increased by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC boosted its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 101.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,695 shares of the biopharmaceutical company's stock after buying an additional 4,386 shares during the quarter. Knights of Columbus Asset Advisors LLC's holdings in Madrigal Pharmaceuticals were worth $2,012,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Madrigal Pharmaceuticals by 7.4% during the third quarter. Vanguard Group Inc. now owns 1,573,338 shares of the biopharmaceutical company's stock worth $229,770,000 after buying an additional 107,816 shares during the period. BlackRock Inc. grew its position in Madrigal Pharmaceuticals by 9.6% during the second quarter. BlackRock Inc. now owns 1,043,537 shares of the biopharmaceutical company's stock worth $241,057,000 after buying an additional 91,027 shares during the period. State Street Corp grew its position in Madrigal Pharmaceuticals by 17.1% during the third quarter. State Street Corp now owns 966,641 shares of the biopharmaceutical company's stock worth $62,822,000 after buying an additional 141,334 shares during the period. Perceptive Advisors LLC grew its position in Madrigal Pharmaceuticals by 50.6% during the first quarter. Perceptive Advisors LLC now owns 650,562 shares of the biopharmaceutical company's stock worth $157,605,000 after buying an additional 218,630 shares during the period. Finally, FMR LLC grew its position in Madrigal Pharmaceuticals by 26.2% during the third quarter. FMR LLC now owns 440,380 shares of the biopharmaceutical company's stock worth $64,313,000 after buying an additional 91,337 shares during the period. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Richard S. Levy sold 11,000 shares of the company's stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $257.48, for a total transaction of $2,832,280.00. Following the completion of the transaction, the director now owns 10,298 shares of the company's stock, valued at $2,651,529.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director James M. Daly sold 32,489 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $102.77, for a total value of $3,338,894.53. Following the completion of the sale, the director now owns 1,198 shares of the company's stock, valued at $123,118.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard S. Levy sold 11,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $257.48, for a total transaction of $2,832,280.00. Following the completion of the sale, the director now directly owns 10,298 shares of the company's stock, valued at approximately $2,651,529.04. The disclosure for this sale can be found here. Over the last quarter, insiders sold 146,496 shares of company stock valued at $31,362,420. Insiders own 23.92% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on MDGL. JMP Securities upped their target price on shares of Madrigal Pharmaceuticals from $351.00 to $397.00 and gave the stock an "outperform" rating in a research report on Friday, March 15th. B. Riley raised shares of Madrigal Pharmaceuticals from a "sell" rating to a "neutral" rating and upped their price target for the company from $155.00 to $270.00 in a report on Friday, March 15th. Oppenheimer upped their price target on shares of Madrigal Pharmaceuticals from $320.00 to $375.00 and gave the company an "outperform" rating in a report on Friday, March 15th. UBS Group upped their price target on shares of Madrigal Pharmaceuticals from $337.00 to $410.00 and gave the company a "buy" rating in a report on Friday, March 15th. Finally, Canaccord Genuity Group upped their price target on shares of Madrigal Pharmaceuticals from $338.00 to $377.00 and gave the company a "buy" rating in a report on Friday, March 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $377.40.

Madrigal Pharmaceuticals Trading Down 4.6 %

Shares of MDGL traded down $10.22 on Friday, hitting $212.04. 625,155 shares of the stock traded hands, compared to its average volume of 337,309. The company has a quick ratio of 5.38, a current ratio of 5.38 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $4.22 billion, a P/E ratio of -10.63 and a beta of -0.47. The stock's 50 day moving average is $244.69 and its two-hundred day moving average is $210.93. Madrigal Pharmaceuticals, Inc. has a 1 year low of $119.76 and a 1 year high of $322.67.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($5.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.26) by ($0.42). During the same quarter last year, the firm earned ($4.98) EPS. As a group, sell-side analysts predict that Madrigal Pharmaceuticals, Inc. will post -21.48 earnings per share for the current year.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.